Association of rituximab use with adverse events in adults with lymphoma or autoimmune disease: a single center experience
Our findings indicated AEs were common during RTX treatment, particularly in lymphoma patients, most of which were moderate and mild, highlighting a whole-process monitoring, timely interference and caring. And RTX was a safe and effective therapeutic option for pMN either as initial or alternative therapy in adult Chinese patients.
Authors
- Rong Wang (ORCID: https://orcid.org/0000-0001-7342-5278)
- Bing Zhao (ORCID: https://orcid.org/0000-0001-5423-971X)
- Jiangong Lin
- Mengsi Hu
- Zhimei Lv (ORCID: https://orcid.org/0000-0001-5128-4734)
- Qi Guo (ORCID: https://orcid.org/0000-0003-4188-6883)
- Bing Liu (ORCID: https://orcid.org/0000-0003-2029-5187)
- Tingwei Zhang
Institutions
- Qingdao University (CN)
- Shandong University (CN)
- Shandong Provincial Hospital (CN)
- Taian City Central Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-04-25
- DOI
- https://doi.org/10.3389/fmed.2025.1567886
- Citations
- 2
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 3.25
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Shandong First Medical University